Clinical Trial Update: Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease [Phase 2]

View source ↗

Summary

Phase 2 long-term safety results of vedolizumab (MLN0002) in patients with ulcerative colitis and Crohn's disease have been reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Ulcerative Colitis

Drugs mentioned

• Vedolizumab (vedolizumab)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Ulcerative Colitis, Crohn's Disease | Phase 2 | Status: COMPLETED | Results posted: 2014-07-18